Depakene

Migraine, Acute Coryza, Behcet Syndrome + 4 more
Treatment
20 Active Studies for Depakene

What is Depakene

Valproic acidThe Generic name of this drug
Treatment SummaryValproic acid, also known as valproate, is a type of medication used to reduce seizures in people with epilepsy. It was first discovered in 1881, but it wasn’t until 1963 that its anticonvulsant effects were discovered. The FDA approved the drug in 1978 under the brand name Depakene. Today, valproic acid is also used to treat mania, migraine, and some types of cancer. It is being studied in clinical trials for its potential to slow down or stop the growth of cancer cells.
Depakeneis the brand name
Depakene Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Depakene
Valproic acid
1978
481

Effectiveness

How Depakene Affects PatientsValproate can help reduce seizures and migraine headaches, as well as manage symptoms of bipolar disorder. It is thought to work by increasing the inhibition of neural activity in the brain and helping to prevent damage and degeneration. However, Valproate can be toxic to the liver and cause birth defects. A study showed that it can help clear HIV when combined with other treatments, but this was not replicated in a larger trial. The FDA label for this drug contains a warning about HIV reactivation.
How Depakene works in the bodyValproate works in the body in several ways to treat epilepsy, migraine headaches, and bipolar disorder. First, it increases GABA activity, which is an inhibitory neurotransmitter. It also activates certain pathways in the brain, like ERK and PKC, that lead to increased neurogenesis and anti-apoptosis. In addition, it decreases the production of inflammatory prostaglandins, which is helpful in preventing migraines. Finally, it acts as a histone deacetylase inhibitor, which helps regulate gene expression and provide neuroprotective effects.

When to interrupt dosage

The recommended dosage of Depakene is contingent upon the diagnosed situation, such as Seizures, Seizure, Absence and Complex Partial Seizures. The amount of dosage varies as per the approach of delivery (e.g. Injection, solution - Intravenous or Capsule, delayed release) detailed in the table below.
Condition
Dosage
Administration
Behcet Syndrome
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Mental Depression
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Migraine
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Acute Coryza
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Seizures
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Seizures
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release
Epilepsy
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule, Capsule - Oral, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Tablet - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection, Injection - Intravenous, Syrup, Syrup - Oral, Liquid, Liquid - Intravenous, Capsule, Delayed Release - Oral, Capsule, Delayed Release

Warnings

Depakene has five contraindications and should not be taken when experiencing the circumstances listed in the ensuing table.Depakene Contraindications
Condition
Risk Level
Notes
Mitochondrial Diseases
Do Not Combine
Liver Failure
Do Not Combine
Disease
Do Not Combine
Liver Diseases
Do Not Combine
Enzymes
Do Not Combine
There are 20 known major drug interactions with Depakene.
Common Depakene Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Valproic acid.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Valproic acid.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Valproic acid.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Valproic acid.
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Valproic acid.
Depakene Toxicity & Overdose RiskThe toxic dose of Valproate in mice is 1098mg/kg and in rats is 670mg/kg. Symptoms of an overdose may include drowsiness, slowed heart rate, deep coma, and high levels of salt in the blood. In some cases, death has been reported, though people have survived with Valproate levels as high as 2120 mcg/mL. Hemodialysis can be used to remove the unbound portion of the drug. Women who take Valproate during pregnancy may put their child at an increased risk of birth defects, autism spectrum disorder, and even death in some cases. Valpro

Depakene Novel Uses: Which Conditions Have a Clinical Trial Featuring Depakene?

65 ongoing trials are analyzing the potential of Depakene to alleviate Migraine, Complex Partial Seizures and Acute Coryza.
Condition
Clinical Trials
Trial Phases
Migraine
53 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Seizures
0 Actively Recruiting
Seizures
0 Actively Recruiting
Acute Coryza
1 Actively Recruiting
Not Applicable
Behcet Syndrome
1 Actively Recruiting
Not Applicable
Epilepsy
0 Actively Recruiting
Mental Depression
2 Actively Recruiting
Phase 2, Not Applicable

Patient Q&A Section about depakene

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Depakote and Depakene the same thing?

"The key difference between Depakene and Depakote is that Depakene is made of valproic acid only whereas Depakote is made by combining valproic acid and sodium valproate in a lab."

Answered by AI

What is Depakene used to treat?

"This medication is used to prevent or treat seizure disorders and mental/mood conditions such as the manic phase of bipolar disorder. It works by restoring the balance of certain neurotransmitters in the brain."

Answered by AI

What is another name for Depakene?

"Valproic acid is commonly used to treat seizures and is the generic name for the widely used medication. The brand name for valproic acid in the United States and Canada is Depakene."

Answered by AI

What kind of drug is Depakene?

"Depakene is an antiepileptic medication used to treat various types of seizure disorders. It is sometimes used in combination with other seizure medications. Depakene is also available in generic form."

Answered by AI

Clinical Trials for Depakene

Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Waitlist Available
Has No Placebo
Johns Hopkins MedicineRisheng Xu, MD, PhDMedtronic
Image of University of the Fraser Valley in Chilliwack, Canada.

Mind-Body App + Movement Program for Chronic Pain

19 - 75
All Sexes
Chilliwack, Canada
The investigators are evaluating the effects of a mind-body mobile application, in combination with a guided movement program, on the experience of chronic pain. Participants meeting the criteria for chronic/persistent pain (confirmed via self-report) will complete an online baseline questionnaire. Eligible participants will take part in an intervention that involves use of a 6-week free trial of a mind-body focused mobile application in combination with virtual asynchronous audio-guided somatic education sessions (gentle movement). External data from a usual care control arm and a mobile-app-only arm from a previous study by the same research team, National Clinical Trials (NCT) registry number NCT05090683, will be used for comparison with the current combined intervention. All participants will complete online surveys at the start of the study and after 6 weeks to measure pain intensity and interference (primary outcomes), mental health outcomes (depression, anxiety, stress), pain-related thoughts (pain catastrophizing), quality of life, and fear of movement (secondary outcomes). From weeks 2 to 6, participants will fill out weekly surveys to track how often they engage with each: the somatic education (gentle movement) program and the mobile app. Participants will also complete a follow-up survey at 12 weeks (6 weeks post-intervention conclusion).
Waitlist Available
Has No Placebo
University of the Fraser ValleyCynthia J Thomson, PhD
Image of Mount Sinai Hospital in New York, United States.

Rimegepant + Zavegepant for Migraine

18+
All Sexes
New York, NY
This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor antagonists are FDA-approved for the indication of acute migraine treatment, past studies have been limited to the outpatient setting. If these medications are effective in the Emergency Department, their delivery methods alone may have advantages over intravenous medications commonly used for acute migraine in EDs, including quicker time to treatment delivery, faster pain relief, and reduced ED length of stay. This investigation is a pilot study to examine rimegepant and zavegepant in an ED, to gain insight on effectiveness in this setting. This study will administer rimegepant 75 mg ODT single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments to 100 patients in the Emergency Department. It is a single center, open-label, non-controlled 2-group clinical trial (allocated 1:1 to rimegepant or zavegepant via pseudo-random assignment). The study will enroll adults in the ED meeting ICHD-3 criteria for migraine or probable migraine, with or without aura.
Phase 4
Recruiting
Mount Sinai HospitalJonathan SchimmelPfizer
Have you considered Depakene clinical trials? We made a collection of clinical trials featuring Depakene, we think they might fit your search criteria.Go to Trials
Image of University of Minnesota in Minneapolis, United States.

Visual Adaptation for Visual Snow

18 - 60
All Sexes
Minneapolis, MN
The goal of this study is to learn more about the brain pathways and activity involved in creating Visual Snow Syndrome (VSS). The main questions it aims to answer are: * Does VSS arise from spontaneous activity in brain pathways? * Where in the brain does the activity contributing to VSS arise? * How does brain activity contribute to VSS? Participants will: 1. Undergo assessments and questionnaires to understand visual and mental symptoms, cognitive, and sensory function. 2. Make visual judgements based on images presented to them both inside and outside a magnetic resonance imaging (MRI) machine. 3. Undergo scanning of their brain while inside of an MRI machine.
Recruiting
Paid Trial
University of MinnesotaMichael-Paul Schallmo, Ph.D.
Image of HCA Florida north florida Hospital in Gainesville, United States.

Bupivacaine Injection for Headache

18+
All Sexes
Gainesville, FL
Headache is a frequent chief complaint among patients presenting to the Emergency Department (ED), accounting for 2.1 million visits annually in the United States. Often, individuals resort to ED care only after over-the-counter or home remedies have failed, leading to the predominant use of intravenous (IV) medications in the ED, including NSAIDs, triptans, neuroleptics, antiepileptics, and dopaminergic antagonists. Unfortunately, these pharmacologic treatments frequently induce side effects such as cognitive impairment, extrapyramidal reactions, and the potential for medication dependency. In the ED, patients frequently require concurrent administration of multiple systemic medications to achieve satisfactory pain relief, thereby elevating the risk associated with medication use. Despite these medication regimens, a significant portion of patients continue to experience inadequate pain relief. Consequently, the search for an optimal headache therapy-characterized by rapid and effective pain relief, long lasting results, minimal side effects, and allows for rapid ED patient turnover-continues to be a popular area of research in emergency medicine. The investigators plan to evaluate the use of 0.5% bupivacaine cervical IM injection at the c6-7 location for the treatment of non traumatic headaches using a non-inferiority design, randomized, prospective, open-label, controlled trial comparing it to physicians choice of intravenous medications in treatment of headache in the Emergency Department at North Florida Hospital.
Phase 3
Waitlist Available
HCA Florida north florida HospitalRobyn Hoelle, MD
Have you considered Depakene clinical trials? We made a collection of clinical trials featuring Depakene, we think they might fit your search criteria.Go to Trials
Image of Brigham and Women's Hospital in Boston, United States.

Cocoa Extract for Migraine

18+
All Sexes
Boston, MA
The goal of this clinical trial is to assess the feasibility of recruitment and adherence to a high-dose cocoa extract supplement in individuals diagnosed with episodic migraine. The main questions it aims to answer are: * Will we be able to enroll 114 participants during the recruitment period? * Will participants take study pills daily during the pill-taking period? Researchers will compare two doses of cocoa extract to placebo to determine the acceptability of higher doses of cocoa extract supplementation in this patient population. Participants will be asked to: * Provide two urine samples * Complete daily questionnaires * Take four study pills a day for 12 weeks
Recruiting
Dietary Supplement
Brigham and Women's HospitalPamela M Rist, ScD
Have you considered Depakene clinical trials? We made a collection of clinical trials featuring Depakene, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security